GeoVax files S-1 for resale of 11.4 million warrant shares tied to August inducement

GeoVax Labs filed a Form S-1 with the SEC on September 17, 2026, covering the potential resale of up to 11,395,256 shares of common stock issuable upon exercise of a common stock purchase warrant issued to an institutional investor in connection with a warrant exercise inducement that occurred on August 25, 2026¹.

The filing describes GeoVax as a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms¹. Its stated near-term priority is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox, smallpox, and other poxviruses¹, with plans to initiate a pivotal Phase 3 clinical trial in the fourth quarter of 2026¹ under an expedited European regulatory pathway. Its oncology candidate, Gedeptin, a novel oncolytic solid tumor gene-directed therapy, recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers¹. A follow-on study pairing Gedeptin with a checkpoint inhibitor is planned to initiate during the second half of 2027, evaluated as first-line treatment for patients with squamous cell head and neck cancer who are eligible for curative surgery¹.

On the underlying inducement deal, a holder of existing warrants covering 5,697,628 shares, with exercise prices ranging from $1.36 to $2.31, agreed to exercise them for cash at a reduced price of $0.64 per share, in exchange for the company's agreement to issue the new warrant covering up to 11,395,256 shares¹. Net proceeds from that transaction, after deducting fees and expenses and excluding any proceeds from future cash exercise of the new warrant, were approximately $3,341,000.¹

Financially, the company disclosed that it incurred a net loss of approximately $21.5 million for the year ended December 31, 2025 and approximately $9.7 million for the six months ended June 30, 2026¹. It also said it has received a "going concern" opinion from its independent registered public accounting firm, reflecting substantial doubt about its ability to continue as a going concern¹, and that existing cash and cash equivalents are sufficient to fund operations into October 2026¹. Common stock, listed on Nasdaq under the symbol "GOVX," last closed at $0.43 per share on September 14, 2026¹.